Levels of circulating cytokines in children with multiple sclerosis with different effectiveness of interferon therapy-Reference-Cited by-同舟云学术

Levels of circulating cytokines in children with multiple sclerosis with different effectiveness of interferon therapy

Published:2024-01-08 Issue:4 Volume: Page:31-39
ISSN:2712-7958
Container-title:Allergology and Immunology in Paediatrics
language:
Short-container-title:jour

Author:

Radygina T. V.¹^ORCID,Petrichuk S. V.¹^ORCID,Kurbatova O. V.¹^ORCID,Kuptsova D. G.¹^ORCID,Fisenko A. P.¹^ORCID,Semikina E. L.¹^ORCID,Freydlin E. V.¹^ORCID,Abdullaeva L. M.¹^ORCID,Bursagova B. I.¹^ORCID

Affiliation:

1. FSAI “National Medical Research Center of Children’s Health” under the Ministry of Health of Russia

Abstract

Multiple sclerosis (MS) is a chronic, demyelinating disease that leads to disability. Understanding the etiology of MS contributes to the development of pathogenetic methods of treatment, and the search for informative biomarkers of the effectiveness of treatment will allow the patient to adjust therapy in time. The aim of this work was to determine informative cytokines and cytokine profiles to predict the effectiveness of IFN-β1a therapy in children with MS.Materials and methods. 66 children with MS aged 16 [14.2–17.5] years who are on INFß-1a therapy were examined: group 1 — patients with exacerbation of MS (with active foci of demyelination by MRI), n = 34; group 2 — patients in remission of MS (without active foci), n = 32. The content of cytokines in the blood serum of patients was assessed using the multiplex panel Human Th17 Magnetic Bead Panel.Results: There was a significant increase in cytokine concentrations in patients with exacerbation of MS compared with children in remission: IL5, IL6, IL9, IL12p70, IL17E/IL25, IL21, IL28A, GM-CSF, TNFß. Threshold values for IL9 (AUC = 0,785), IL6 (AUC = 0,750), TNFß (0,740), IL28A (AUC = 0,744) were obtained above which it is possible to predict an exacerbation of MS in patients: IL9 — 3.9 pg/ml (Sn — 70.6, Sp — 71.9), IL6 — 4.0 pg/ml (Sn — 70.6, Sp — 68.8), TNFß — 6.6 pg/ml (Sn — 70.6, Sp — 71.9), IL28A — 243.0 pg/ml (Sn — 70.6, Sp — 71.9). Cytokine profiles associated with T-lymphocytes and their functions were evaluated using z-score.Conclusions. For the first time, an increase in cytokine levels was demonstrated in children with active foci of demyelination compared to patients in remission of MS. An increase in proinflammatory cytokines and cytokine profiles associated with Th1 and Th17, as well as with Th2 and Th22 has been shown. The use of threshold values for IL9, IL6, TNFβ, IL28A will help predict the development of exacerbation in patients with MS.

Publisher

Association of Pediatric Allergologists and Immunologists of Russia

Reference22 articles.

1. Walton C, King R, Rechtman L, Kaye W, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26 (14): 1816–1821. https://doi.org/10.1177/1352458520970841.

2. Boynova IV, Samarina DV, Katorova AV, Tokareva NG. Clinical and epidemiological features of multiple scle rosis in the Russian Federation. Sovremennye problemy nauki i obrazovanija. 2022; 5. https://science-education.ru/ru/article/ view?id=32006. (In Russ.)

3. Wei W, Ma D, Li L and Zhang L. Progress in the application of drugs for the treatment of multiple sclerosis. Front. Pharmacol. 2021; 12: 724718. https://doi.org/10.3389/fphar.2021.724718.

4. Kulikova S, Kuzniatsova A, Likhachev S, Golets Y. Pediatric multiple sclerosis: diagnostics and treatment (Review). Neurology and Neurosurgery. Eastern Europe. 2021; 11 (1): 69–81. (In Russ.)

5. Abdullaeva LM, Bursagova BI, Kurenkov AL, Kuzenkova LM. Treatment of multiple sclerosis in children: review of clinical trials L. O. Badalyan neurological journal. 2023; 4 (1): 43–51. https://doi.org/10.46563/2686-8997-2023-4-1-43-51. (In Russ.)